Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other therapeutic areas. The recruitment and retention of a large number of qualified, diverse volunteers to participate in clinical research studies remain among the key barriers to the successful completion of AD clinical trials. An advisory panel of experts from academia, patient-advocacy organizations, philanthropy, non-profit, government, and industry convened in 2020 to assess the critical challenges facing recruitment in Alzheimer's clinical trials and develop a set of recommendations to overcome them. This paper briefly reviews existing challenges in AD clinical research and discusses the feasibility and implications of the panel's recommendations for actionable and inclusive solutions to accelerate the development of novel therapies for AD.

中文翻译：

---

解决阿尔茨海默病临床试验关键招募挑战的建议

与大多数其他治疗领域的试验相比，阿尔茨海默病 (AD) 的临床试验招募研究参与者的速度较慢，完成时间较长，而且费用更高。招募和保留大量合格的、多样化的志愿者参与临床研究仍然是成功完成 AD 临床试验的主要障碍之一。来自学术界、患者权益组织、慈善机构、非营利组织、政府和行业的专家顾问小组于 2020 年召开会议，评估阿尔茨海默氏症临床试验招募人员面临的关键挑战，并制定一系列建议来克服这些挑战。本文简要回顾了 AD 临床研究中现有的挑战，并讨论了专家组关于可操作和包容性解决方案的建议的可行性和影响，以加速 AD 新型疗法的开发。